MARKET

TOVX

TOVX

THERIVA BIOLOGICS INC
AMEX
0.6975
-0.0075
-1.06%
After Hours: 0.6974 -0.0001 -0.01% 16:22 11/25 EST
OPEN
0.6800
PREV CLOSE
0.7050
HIGH
0.7200
LOW
0.6800
VOLUME
13.80K
TURNOVER
0
52 WEEK HIGH
4.394
52 WEEK LOW
0.5750
MARKET CAP
11.05M
P/E (TTM)
-0.5171
1D
5D
1M
3M
1Y
5Y
Theriva Biologics GAAP EPS of -$0.33
Seekingalpha · 11/10 22:42
BRIEF-Theriva Biologics Reports Third Quarter 2022 Operational Highlights And Financial Results
Reuters · 11/10 22:34
Theriva Biologics Q3 EPS $(0.33) Beats $(0.39) Estimate
Benzinga · 11/10 22:13
Earnings Outlook For Theriva Biologics
Benzinga · 11/10 14:34
Theriva Biologics To Reschedule Conference Call And Webcast To Discuss Q3 2022 Operational Highlights And Financial Results To Friday November 11
Benzinga · 11/10 12:44
A Preview Of Theriva Biologics's Earnings
Benzinga · 11/09 19:10
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need,...
GlobeNewswire · 11/03 20:05
Theriva Biologics Announces First Patient Dosed In Second Cohort Of Phase 1b/2a Clinical Trial Of SYN-004 In Allogeneic Hematopoietic Cell Transplant Recipients
Benzinga · 11/03 12:18
More
About TOVX
Theriva Biologics, Inc., formerly Synthetic Biologics, Inc., is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of unmet need. The Company is engaged in the development of oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a sustained anti-tumor response by the patient's immune system. Its lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier; SYN-004 (ribaxamase) which is designed to degrade IV beta-lactam antibiotics within the gastrointestinal (GI) tract, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under current good manufacturing practice (cGMP) conditions and intended to treat both local GI and systemic diseases.

Webull offers kinds of Theriva Biologics Inc stock information, including AMEX:TOVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TOVX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TOVX stock methods without spending real money on the virtual paper trading platform.